Vir Biotechnology (NASDAQ:VIR – Get Free Report) had its price objective raised by Leerink Partners from $18.00 to $20.00 in ...

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target ...

Vir Biotechnology Inc (VIR) stock saw a decline, ending the day at $12.1 which represents a decrease of $-0.38 or -3.04% from the prior close of $12.48. The stock opened at $12.69 and touched a low of ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.

Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): ...

Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...

August Global Partners will assist Gene Solutions in enhancing the performance of their oncology solutions by providing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...